Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Gaurav Nigade"'
Autor:
Amit Rauthan, Nitin Yashas Murthy, Poonam Patil, Gaurav Nigade, SP Somashekhar, Shabber S. Zaveri
Publikováno v:
South Asian Journal of Cancer, Vol 11, Iss 02, Pp 133-139 (2022)
Abstract Amit Rauthan Introduction Nivolumab monotherapy is approved for the treatment of metastatic renal cell carcinoma (mRCC) patients who have progressed on prior therapies based on the pivotal Checkmate-025 trial. There is limited literature o
Externí odkaz:
https://doaj.org/article/764e9eb38daa4eb2a4fc19265d9cbded
Publikováno v:
Journal of Thoracic Oncology. 16:S763-S764
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::870da833a8b6e862bd0b5c8f352da7e1
https://doi.org/10.1016/s1556-0864(21)01962-6
https://doi.org/10.1016/s1556-0864(21)01962-6
Autor:
Poonam Patil, C. Jomi, Gaurav Nigade, Shabber Zaveri, P. Vundemodalu, S. Sampige Prasannakumar, Amit Rauthan, R. Ashwath, Nitin Yashas Murthy
Publikováno v:
Annals of Oncology. 32:S393
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::117787f8ae7e02125c0ce2a48e82c03a
https://doi.org/10.1016/j.annonc.2021.08.364
https://doi.org/10.1016/j.annonc.2021.08.364
Autor:
Poonam Patil, Amit Rauthan, Shabber Zaveri, Rajshri Ashwath, Prathyush Vundemodalu, S.P. Somashekhar, Aditi Raghunathan, Kakoli Lahkar, K. Gupta, Gaurav Nigade, Nitin Yashas Murthy
Publikováno v:
Cancer Research. 80:4469-4469
Introduction: Immune check point inhibitors(ICI) have revolutionized the treatment of metastatic malignancies. There is a need for a bio-marker apart from PDL-1 especially in a 2nd line setting in malignancies like metastatic renal cell carcinoma (mR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d42ce0794e40d5a929142f0c77408605
https://doi.org/10.1158/1538-7445.am2020-4469
https://doi.org/10.1158/1538-7445.am2020-4469
Autor:
Gaurav Nigade, Shabber Zaveri, Nitin Yashas Murthy, S. P. Somashekhar, K. Lahkar, T. Sood, S.S. Kulkarni, K. Gupta, Poonam Patil, Amit Rauthan
Publikováno v:
Annals of Oncology. 30:xi5
Background There exists a need for a prognostic marker apart from PDL1 expression for patients being treated with immunotherapy. Neutrophil lymphocyte ratio (NLR) has been shown to correlate with outcomes in certain malignancies treated with immune c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::287d9c11b19129ad312542afe2820d9d
https://doi.org/10.1093/annonc/mdz447.014
https://doi.org/10.1093/annonc/mdz447.014
Autor:
S.P. Somashekhar, Nitin Yashas, T. Sood, Amit Rauthan, S.S. Kulkarni, Shabber Zaveri, Poonam Patil, Gaurav Nigade
Publikováno v:
Journal of Clinical Oncology. 37:e16078-e16078
e16078 Background: Nivolumab is now a standard 2nd line treatment for patients of metastatic Renal cell cancer (mRCC) who progress on 1st line Sunitinib or Pazopanib. Most western centers use Nivolumab for either 2 years duration, or indefinitely, or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22b73a9680f0483b1535034258c4a184
https://doi.org/10.1200/jco.2019.37.15_suppl.e16078
https://doi.org/10.1200/jco.2019.37.15_suppl.e16078
Autor:
Poonam Patil, Shabber Zaveri, Gaurav Nigade, Nitin Yashas, Amit Rauthan, T. Sood, S.S. Kulkarni, S.P. Somashekhar
Publikováno v:
Journal of Clinical Oncology. 37:e14073-e14073
e14073 Background: Pembrolizumab is approved for deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) metastatic solid tumors with objective response rate (ORR) of 39.6% and response lasting for more than 6 months in 78% patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97523e148f159d1b45f6b78f191920c6
https://doi.org/10.1200/jco.2019.37.15_suppl.e14073
https://doi.org/10.1200/jco.2019.37.15_suppl.e14073
Autor:
Rauthan, Amit, Murthy, Nitin Yashas, Patil, Poonam, Nigade, Gaurav, Somashekhar, SP, Zaveri, Shabber S.
Publikováno v:
South Asian Journal of Cancer; Apr2022, Vol. 11 Issue 2, p133-139, 7p